Search results for "COMB"

showing 10 items of 7115 documents

Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study.

2011

To retrospectively assess the efficacy of bendamustine alone and with rituximab (R-B), 109 patients with relapsed chronic lymphocytic leukaemia (CLL) were enrolled in 24 Italian centres. The median age was 66 years (range 39-85). Forty-three percent of patients had relapsed and 57% were resistant (median previous therapies = 3; range 1-8). Twenty-two patients received bendamustine alone and 87 patients received R-B (median B dosage: 100 mg/m(2) per day, range 90-130 mg/m(2) per day). The overall response rate was 69·6% (complete response 28·6%; partial response 41%), and was significantly higher in patients treated with R-B (P = 0·014) and in those responsive to the previous treatment (P=0·…

AdultAged 80 and overMaleAntineoplastic AgentsMiddle AgedLeukemia Lymphocytic Chronic B-CellAntibodies Monoclonal Murine-DerivedTreatment OutcomeDrug Resistance NeoplasmRecurrenceAntineoplastic Combined Chemotherapy ProtocolsNitrogen Mustard CompoundsBendamustine HydrochlorideDrug EvaluationHumanschronic lymphocytic leukemiaFemaleChronic lymphocytic leukemia; bendamustineBendamustinaEpidemiologic MethodsRituximabAged
researchProduct

A combined treatment regimen for chronic desquamative gingivitis in patients with oral lichen planus

2007

Background: Chronic desquamative gingivitis (DG) is a condition characterized by erythema, ulceration, and desquamation of the free and attached gingiva, usually expression of a district-systemic disease, such as oral lichen planus (OLP). Methods: A combined protocol of oral hygiene and topic corticosteroid therapy was applied in 30 patients with DG associated with OLP. Plaque index (PI) and bleeding on probing (BoP) were evaluated at baseline and after 3 months. Results: PI scoring was significantly lower after treatment in anterior, posterior, and all sites (P < 0.0001) as well as in vestibular and lingual ones (P < 0.0001 and P = 0.0001, respectively). BoP measures were found to be reduc…

AdultAged 80 and overMalechronic desquamative gingivitiDental Plaque IndexMiddle AgedCombined Modality TherapyStatistics NonparametricGingivitis Necrotizing Ulcerativeoral lichen planusAdrenal Cortex Hormonesbleeding gingival statuDental ScalingHumansFemaleSingle-Blind MethodPeriodontal Indexdental plaque controlAgedLichen Planus Oral
researchProduct

Dosage individualization of erythropoietin using a profile-dependent support vector regression

2003

The external administration of recombinant human erythropoietin is the chosen treatment for those patients with secondary anemia due to chronic renal failure in periodic hemodialysis. The objective of this paper is to carry out an individualized prediction of the EPO dosage to be administered to those patients. The high cost of this medication, its side-effects and the phenomenon of potential resistance which some individuals suffer all justify the need for a model which is capable of optimizing dosage individualization. A group of 110 patients and several patient factors were used to develop the models. The support vector regressor (SVR) is benchmarked with the classical multilayer percept…

AdultAnemia HemolyticInjections SubcutaneousAutoregressive conditional heteroskedasticityBiomedical EngineeringMachine learningcomputer.software_genreCohort StudiesHemoglobinsRenal DialysisFeature (machine learning)HumansMedicineSensitivity (control systems)Time seriesErythropoietinAgedAged 80 and overArtificial neural networkbusiness.industryMiddle AgedRecombinant ProteinsRegressionDrug Therapy Computer-AssistedRegression PsychologySupport vector machineTreatment OutcomeMultilayer perceptronKidney Failure ChronicNeural Networks ComputerArtificial intelligencebusinesscomputerAlgorithmsBiomedical engineeringIEEE Transactions on Biomedical Engineering
researchProduct

Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor s…

1997

Fifty-five consecutive patients with metastatic breast cancer (MBC) (n = 57) were treated with a combination of levofolinic acid (I-FA) 100 mg/m2 plus 5-fluorouracil (5-FU) 340 mg/m2 i.v. on day 1-3, cyclophosphamide (CTX) 600 mg/m2 i.v. on day 1 and mitoxantrone (DHAD) 12 mg/m2 i.v. on day 1. DHAD dose was progressively escalated by 2 mg/m2/cycle up to 18 mg/m2 in the absence of dose-limiting toxicities. Granulocyte colony stimulating factor (G-CSF) was given s.c. in order to prevent neutropenia. DHAD dosage could be increased to 18 mg/m2 in 66 out of 317 cycles of chemotherapy (21%). In most patients the dose-limiting toxicity was represented by myelosuppression. A statistically significa…

AdultAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentAntidotesLeucovorinAntineoplastic AgentsBreast NeoplasmsPharmacologyNeutropeniaGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorHumansMedicinePharmacology (medical)Antineoplastic Agents AlkylatingCyclophosphamideAgedPharmacologyMitoxantroneChemotherapybusiness.industryMiddle Agedmedicine.diseaseMetastatic breast cancerGranulocyte colony-stimulating factorItalyOncologyToxicityAbsolute neutrophil countFemaleFluorouracilMitoxantronebusinessmedicine.drugAnti-Cancer Drugs
researchProduct

Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRI…

2022

Objective: Post-stroke epilepsy (PSE) is one of the most common causes of acquired epilepsy and accounts for about 10-15% of all newly diagnosed epilepsy cases. However, evidence about the clinical profile of antiseizure medications in the PSE setting is currently limited. Brivaracetam (BRV) is a rationally developed compound characterized by high-affinity binding to synaptic vesicle protein 2A. The aim of this study was to assess the 12-month effectiveness and tolerability of adjunctive BRV in patients with PSE treated in a real-world setting. Methods: This was a subgroup analysis of patients with PSE included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). The BRIVAFI…

AdultAntiseizure medication; Brivaracetam; Cerebrovascular diseases; Focal seizures; StrokeCerebrovascular diseasesSettore MED/26Antiseizure medication Brivaracetam Focal seizures Stroke Cerebrovascular diseasesFocal seizuresDouble-Blind MethodDrug TherapySeizuresHumansAgedRetrospective StudiesAntiseizure medicationEpilepsyGeneral MedicineMiddle AgedPyrrolidinonesStrokeTreatment OutcomeNeurologyItalyCombinationBrivaracetamAntiseizure medication; Brivaracetam; Cerebrovascular diseases; Focal seizures; Stroke; Adult; Aged; Anticonvulsants; Double-Blind Method; Drug Therapy Combination; Humans; Italy; Middle Aged; Pyrrolidinones; Retrospective Studies; Seizures; Treatment Outcome; Epilepsy; StrokeDrug Therapy CombinationAnticonvulsantsNeurology (clinical)
researchProduct

Increased thioredoxin levels are related to insulin resistance in familial combined hyperlipidaemia

2015

BACKGROUND Thioredoxins (TRX) are major cellular protein disulphide reductases that are critical for redox regulation. Oxidative stress and inflammation play promoting roles in the genesis and progression of atherosclerosis, but until now scarce data are available considering the influence of TRX activity in familial combined hyperlipidaemia (FCH). Since FCH is associated with high risk of cardiovascular disease, the objective of the present study was to assess oxidative stress status in FCH patients, and evaluate the influence of insulin resistance (IR). MATERIALS AND METHODS A cohort of 35 control subjects and 35 non-related FCH patients were included, all of them nondiabetic, normotensiv…

AdultBlood GlucoseMale0301 basic medicinemedicine.medical_specialtyanimal structuresmedicine.medical_treatmentClinical BiochemistryHyperlipidemia Familial Combined030204 cardiovascular system & hematologymedicine.disease_causeBiochemistry03 medical and health scienceschemistry.chemical_compoundThioredoxins0302 clinical medicineInsulin resistanceInternal medicinemedicineHumansTriglyceridesGlutathione Disulfidemedicine.diagnostic_testbusiness.industryInsulinCholesterol HDLCase-control studyCholesterol LDLGeneral MedicineGlutathioneMiddle Agedmedicine.diseaseGlutathioneOxidative Stress030104 developmental biologyEndocrinologychemistryCardiovascular DiseasesCase-Control StudiesGlutathione disulfideFemaleInsulin ResistanceThioredoxinLipid profilebusinessOxidative stressEuropean Journal of Clinical Investigation
researchProduct

Role of skeletal muscle-fibre type in regulation of glucose metabolism in middle-aged subjects with impaired glucose tolerance during a long-term exe…

2005

Aim: The aim of this study was to investigate the role of skeletal muscle fibre type in the regulation of glucose metabolism in middle-aged obese subjects with impaired glucose tolerance (IGT) during a 2-year exercise anddietary intervention. Methods: Muscle biopsies (musculus vastus lateralis) were taken from 22 subjects belonging to the intervention group of the Finnish Diabetes Prevention Study [1]. According to their myosin heavy chain (MHC) profile at the baseline, the subjects were divided into two groups: IGT s l o w (n = 10) with a high proportion of MHC I isoforms and IGT f a s t (n = 12) with a high proportion of MHC II isoforms in the vastus lateralis muscle. The intervention con…

AdultBlood GlucoseMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyDiet Reducingendocrine system diseasesVastus lateralis muscleEndocrinology Diabetes and MetabolismMuscle Fibers SkeletalCarbohydrate metabolismImpaired glucose toleranceGlycogen Synthase Kinase 3EndocrinologyInsulin resistanceDiabetes mellitusInternal medicineGlucose IntoleranceWeight LossInternal MedicinemedicineHumansAerobic exerciseObesityMuscle SkeletalGlycogen synthaseExerciseAgedMyosin Heavy Chainsbiologybusiness.industrynutritional and metabolic diseasesSkeletal muscleMiddle Agedmedicine.diseaseCombined Modality Therapymedicine.anatomical_structureEndocrinologybiology.proteinFemalebusinesshormones hormone substitutes and hormone antagonistsFollow-Up StudiesDiabetes, Obesity and Metabolism
researchProduct

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial

2016

OBJECTIVE To compare the efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in patients with type 2 diabetes not achieving adequate glycemic control on metformin alone. RESEARCH DESIGN AND METHODS In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin. Liraglutide was administered once daily at any time of the day. Lixisenatide was administered once daily within 1 h prior to the morning or evening meal. RESULTS At week 26, liraglutide reduced HbA1c (primary end point) more than lixisenatide (estimated treatment difference −0.62% [95% CI −0.8; −0.4]; P &amp;…

AdultBlood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyHypoglycemiaDrug Administration Schedulelaw.inventionYoung Adult03 medical and health sciencesLixisenatidechemistry.chemical_compound0302 clinical medicineRandomized controlled triallawInternal medicineInternal MedicinemedicineClinical endpointHumansHypoglycemic AgentsAgedGlycemicAged 80 and overGlycated HemoglobinAdvanced and Specialized NursingLiraglutidebusiness.industryBody WeightLiraglutideMiddle AgedPostprandial Periodmedicine.diseaseHypoglycemiaMetforminMetforminTreatment OutcomeEndocrinologyDiabetes Mellitus Type 2chemistryDrug Therapy CombinationFemalePeptidesbusinessmedicine.drugDiabetes Care
researchProduct

A study of insulin resistance using the minimal model in nondiabetic familial combined hyperlipidemic patients.

1998

The presence of insulin resistance in 20 male nondiabetic patients with familial combined hyperlipidemia (FCH) and 20 controls of similar age and body mass index (BMI) was investigated using the minimal model method modified by the administration of insulin and an oral glucose tolerance test. The peripheral sensitivity of insulin, expressed as the insulin sensitivity index (Si), was 1.91 ± 1.05 and 2.86 ± 1.19 × 10−4 · min−1 · mU/L in FCH patients and controls, respectively (P < .01), and the corresponding value for the peripheral utilization of glucose independently of insulin (Sg) was 1.70 ± 1.13 in FCH patients and 2.35 ± 0.60 × 10−2 · min−1 in controls (P < .02). In the FCH group, the S…

AdultBlood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentHyperlipidemia Familial CombinedFatty Acids NonesterifiedBody Mass IndexEndocrinologyWaist–hip ratioInsulin resistanceStatistical significanceInternal medicinemedicineDiabetes MellitusHumansInsulinObesityPancreatic hormoneTriglyceridesApolipoproteins Bbusiness.industryInsulinCholesterol HDLArea under the curveAge FactorsMiddle Agedmedicine.diseaseObesityEndocrinologyGlucoseCase-Control StudiesBody ConstitutionInsulin ResistancebusinessBody mass indexMetabolism: clinical and experimental
researchProduct

Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1.

2010

Metabolic factors have been associated with liver damage in patients with genotype 1 chronic hepatitis C (G1 CHC). We tested visceral adiposity index (VAI), a new marker of adipose dysfunction in G1 CHC, patients to assess its association with host and viral factors and its link to both histological findings and sustained virological response (SVR). Two hundred thirtysix consecutive G1 CHC patients were evaluated by way of liver biopsy and anthropometric and metabolic measurements, including insulin resistance (IR), homeostasis model assessment (HOMA), and VAI using waist circumference, body mass index, triglycerides, and highdensity lipoprotein cholesterol. All biopsies were scored by one …

AdultBlood GlucoseMalemedicine.medical_specialtyPathologyAlcohol DrinkingGenotypeInterferon alpha-2Intra-Abdominal FatGastroenterologyAntiviral AgentsBody Mass IndexPolyethylene GlycolsInsulin resistanceInternal medicineDiabetes mellitusmedicineHumansHepatologymedicine.diagnostic_testbusiness.industryCholesterol HDLInterferon-alphaAlanine TransaminaseHepatitis CHepatologyHepatitis C ChronicMiddle AgedViral Loadmedicine.diseaseRecombinant ProteinsFatty LiverDiabetes Mellitus Type 2Liver biopsyHypertensionRNA ViralFemaleSteatosisWaist CircumferencebusinessViral loadBody mass indexHepatology (Baltimore, Md.)
researchProduct